Drugs

, Volume 10, Issue 4, pp 241–323 | Cite as

Fenfluramine

A Review of its Pharmacological Properties and Therapeutic Efficacy in Obesity
  • R. M. Finder
  • R. N. Brogden
  • Phyllis R. Sawyer
  • T. M. Speight
  • G. S. Avery
Evaluations on New Drugs

Summary

Synopsis: Fenfluramine2 has been used for a number of years as a short-term adjunct to diet in the management of obesity. Controlled studies and clinical experience have shown that it possesses anorectic activity at least as good as that of other therapeutically useful drugs of its type, but like these drugs it has only a limited role in the overall management of obesity. Tolerance to the anorectic effects of fenfluramine may possibly develop more slowly than to other chemically related drugs in patients with refractory obesity. The mechanism of its anorectic action is probably by an effect on the appetite control centres in the hypothalamus, rather than by an effect on glucose and lipid metabolism. However, its effect in enhancing glucose uptake into skeletal muscle may be of advantage in diabetes mellitus, preliminary studies suggesting that it is of potential use in maturity-onset obese diabetics who cannot be adequately controlled by dietary measures alone.

The starting dosage in obesity of 40mg daily should be increased gradually over 2 to 4 weeks to 60 to 120mg. In general, little extra benefit is gained by higher dosage. When a course of therapy is to be discontinued, fenfluramine dosage should be reduced gradually over a period of 2 to 4 weeks in order to avoid mood depression which has occurred in some patients on abrupt withdrawal of the drug. With these recommendations, the majority of patients tolerate fenfluramine satisfactorily, although some patients may have to discontinue the drug because of troublesome gastro-intestinal problems, diarrhoea, drowsiness or dizziness. Unlike other amphetamine-derived anorectics, fenfluramine is not a central stimulant in therapeutic doses, and it probably has little abuse potential.

Keywords

Anorectic drugs Carbohydrate metabolism Diabetes mellitus Fenfluramine Lipid metabolism Obesity 

References

  1. Aldous, F.A.B.; Barrass, B.C.; Brewster, K.; Buxton, D.A.; Green, D.M.; Pinder, R.M.; Rich, P.; Skeels, M. and Tutt, K.J.: Structure-activity relationships in psychotomimetic phenylalkylamines. Journal of Medicinal Chemistry 17: 1100 (1974).PubMedCrossRefGoogle Scholar
  2. Alphin, R.S.; Funderburk, W.H. and Ward, J.W.: Anorexigenic activity of N-ethyl-α-methyl-3-trifluoromethylphenethylamine hydrochloride (AHR-965). A non-CNS stimulant. Toxicology and Applied Pharmacology 6: 340 (1964).CrossRefGoogle Scholar
  3. Alphin, R.S. and Ward, J.W.: Anorexigenic effect of fen-fluramine hydrochloride in rats, guinea-pigs, and dogs. Toxicol. appl. Pharmacol. 14: 182 (1969).PubMedCrossRefGoogle Scholar
  4. Anderson, J.: Drugs and appetite. Practitioner 212: 536 (1974).PubMedGoogle Scholar
  5. Arvela, P.; Karki, N.T. and Niominen, L.: Effect of long-term fenfluramine treatment on drug metabolism in the rat. Experientia 29: 454 (1973).PubMedCrossRefGoogle Scholar
  6. Asmal, A.C.; Butterfield, W.J.H. and Whichelow, M.J.: Carbohydrate metabolism in obesity. Proceedings of 2nd International Symposium on the Clinical and Metabolic Aspects of Laevulose (Calmic, London, 1970).Google Scholar
  7. Bacon, G.E. and Lowry, G.H.: A clinical trial of fenfluramine in obese children. Current Therapeutic Research 9: 626 (1967).PubMedGoogle Scholar
  8. Baez, L.A.: Role of catecholamines in the anorectic effects of amphetamine in rats. Psychopharmacologia 35: 91 (1974).PubMedCrossRefGoogle Scholar
  9. Baiasse, E.O.: Effects of fenfluramine, administered on a short or long term basis, on the lipolysis of obese subjects. La Vie Medicale au Canada Francais 2: 157 (1973).Google Scholar
  10. Baiasse, E.O.; Couturier, E.; Kornitzer, M. and Degre, S.: Influence of a long-acting preparation of fenfluramine on body weight, body composition, and skinfold thickness in obese subjects. Postgraduate Medical Journal 51 (Suppl. 1): 153 (1975).Google Scholar
  11. Bartlett, D.W.: Fenfluramine and pigmented naevi. British Medical Journal 3: 115 (1972).PubMedCrossRefGoogle Scholar
  12. Beckett, A.H. and Brookes, L.G.: The absorption and urinary excretion in man of fenfluramine and its main metabolite. Journal of Pharmacy and Pharmacology 19: 42S (1967).PubMedGoogle Scholar
  13. Beckett, A.H. and Brookes, L.G.: The effect of chain and ring substitution on the metabolism, distribution, and biological action of amphetamines. In Costa and Garattini, Amphetamine and Related Compounds, p.109 (Raven Press, New York 1970).Google Scholar
  14. Beckett, A.H.; Coutts, R.T. and Ogunbona, F.A.: N-ethyl-α-methyl-α-(m-trifluoromethylbenzyl)nitrone, the major in vitro metabolic product of fenfluramine in guinea-pig liver microsomal fractions. Journal of Pharmacy and Pharmacology 25: 190 (1973).PubMedCrossRefGoogle Scholar
  15. Beckett, A.H. and Salmon, J.A.: Pharmacokinetics of absorption, distribution, and elimination of fenfluramine and its main metabolite in man. Journal of Pharmacy and Pharmacology 24: 108 (1972).PubMedCrossRefGoogle Scholar
  16. Belvedere, G.; Tognoni, S. and Morsell, P.: A new sensitive gas-chromatographic method for the determination of fenfluramine in biological specimens. European Journal of Clinical Pharmacology 5: 62 (1972).CrossRefGoogle Scholar
  17. Beregi, L.G.; Hugon, P.; Le Douarec, J.C.; Laubie, M. and Duhault, J.: Structure-activity relationships in CF3-substituted phenethylamines. In Costa and Garattini, Amphetamine and Related Compounds, p.21 (Raven Press, New York 1970).Google Scholar
  18. Berger, H.J.; Brown, C.C. and Krantz, J.C.: Fenfluramine blockade of CNS stimulant effects of amphetamines. Journal of Pharmaceutical Sciences 62: 788 (1973).PubMedCrossRefGoogle Scholar
  19. Bernier, A.; Sicot, A. and Le Douarec, J.C.: Action comparee de la fenfluramine et de l’amphetamine chez les rats obeses hypothalamiques. Revue Francaise d’Etudes Clinques et Biologiques 14: 762 (1969).Google Scholar
  20. Biel, J.H.: Structure-activity relationships of amphetamine and derivatives. In Costa and Garattini, Amphetamine and Related Compounds, p.3 (Raven Press, New York 1970).Google Scholar
  21. Bizzi, A.; Bonaccorsi, A.; Jespersen, S.; Jori, A. and Garattini S.: Pharmacological studies on amphetamine and related compounds. In Costa and Garattini, Amphetamine and Related Compounds, p.577 (Raven Press, New York 1970).Google Scholar
  22. Bizzi, A.; Veneroni, E. and Garattini, S.: Effect of fenfluramine on the intestinal absorption of triglycerides. European Journal of Pharmacology 23: 131 (1973).PubMedCrossRefGoogle Scholar
  23. Bliss, B.P.; Kirk, C.J.C. and Newall, R.G.: The effect of fenfluramine on glucose tolerance, insulin, lipid, and lipoprotein levels in patients with peripheral arterial disease. Postgrad, med. J. 48: 409 (1972).CrossRefGoogle Scholar
  24. Blundell, J.E.; Campbell, D.B.; Leshem, M. and Tozer, R.: Comparison of the time course of the anorectic effect of fenfluramine and amphetamine with drug levels in blood. Journal of Pharmacy and Pharmacology 27: 187 (1975).PubMedCrossRefGoogle Scholar
  25. Blundell, J.E.; Latham, C.J. and Leshem, M.B.: Biphasic action of a 5-hydroxytryptamine inhibitor on fenfluramine-induced anorexia. Journal of Pharmacy and Pharmacology 25: 492 (1973).PubMedCrossRefGoogle Scholar
  26. Blundell, J.E. and Leshem, M.B.: Dissociation of the anorexic effects of fenfluramine and amphetamine following intrahypothalamic injection. British Journal of Pharmacology 47: 183 (1973).PubMedCrossRefGoogle Scholar
  27. Blundell, J.E. and Leshem, M.B.: Central action of anorexic agents. Effects of amphetamine and fenfluramine in rats with lateral hypothalamic lesions. European Journal of Pharmacology 28: 81 (1974).PubMedCrossRefGoogle Scholar
  28. Blundell, J.E. and Leshem, M.B.: The effect of 5-hydroxytryptophan on food intake and on the anorexic action of amphetamine and fenfluramine. Journal of Pharmacy and Pharmacology 27: 31 (1975).PubMedCrossRefGoogle Scholar
  29. Bolodeoku, J.O. and Adadevoh, B.K.: Metabolic and clinical effects of fenfluramine in obese patients. Nigerian Medical Journal 4: 13 (1974).Google Scholar
  30. Bolodeoku, J.O.; Adadevoh, B.K. and Palmer, E.O.: Therapeutic effect of fenfluramine (Ponderax) in obese Nigerians — weight reducing and hypotensive properties. Nigerian Medical Journal 2: 199 (1972).Google Scholar
  31. Bompiani, G.D. and Laudicina, E.: Obesity and diabetes. Israel Journal of Medical Sciences 8: 823 (1972).PubMedGoogle Scholar
  32. Brandon, S.: Unusual effect of fenfluramine. British Medical Journal 4: 557 (1969).PubMedCrossRefGoogle Scholar
  33. Brimblecombe, R.W. and Pinder, R.M.: Tremors and tremorogenic agents. (Scientechnica, Bristol 1972).Google Scholar
  34. Brindley, D.N. and Bowley, M.: Effects of fenfluramine and related compounds on the synthesis of glycerolipids by rat liver. Postgraduate Medical Journal 51 (Suppl. 1): 87 (1975).Google Scholar
  35. Brockie, B.K.; Brown, P.; Ahmed, N.; Stirling, H. and Strong, J.A.: Glucose tolerance and the metabolic response to exercise in obese patients treated with fenfluramine. South African Medical Journal 45 (Suppl.): 26 (1971).Google Scholar
  36. Brodbin, P. and O’Connor, C.A.: A double-blind clinical trial of an appetite depressant, fenfluramine, in general practice. Practitioner 198: 707 (1967).PubMedGoogle Scholar
  37. Broekkamp, C.L.E.; Weemaes, A.J.M. and Van Rossum, J.M.: Does fenfluramine act via norfenfluramine? J. Pharm. Pharmacol. 27: 129 (1975).PubMedCrossRefGoogle Scholar
  38. Brookes, L.G.: Excretion and metabolism of some amphetamine analogues. Ph. D. Thesis, London University (1968).Google Scholar
  39. Brown, C.C: Effects of a combination of fenfluramine and amphetamine on psychomotor activity. La Vie Medicale au Canada Francais 2: 148 (1973).PubMedGoogle Scholar
  40. Brown, C.C.; McAlister, D.R. and Turek, I.: Psychomotor test performance with a fenfluramine-amphetamine combination. Journal of Clinical Pharmacology 14: 369 (1974).PubMedGoogle Scholar
  41. Bruce, R.B. and Maynard, W.R.: Fenfluramine metabolism. Journal of Pharmaceutical Sciences 57: 1173 (1968).PubMedCrossRefGoogle Scholar
  42. Burland, W.L.: Drug-dependent South African National Serviceman. South African Medical Journal 47: 43 (1973).PubMedGoogle Scholar
  43. Butterfield, W.J.H. and Whichelow, M.J.: Fenfluramine and muscle glucose uptake in man. Lancet 2: 109 (1968a).CrossRefGoogle Scholar
  44. Butterfield, W.J.H. and Whichelow, M.J.: Effect of diet, sulphonylureas, and phenformin on peripheral glucose uptake in diabetes and obesity. Lancet 2: 785 (1968b).PubMedCrossRefGoogle Scholar
  45. Butterfield, W.J.H.; Whichelow, M.J.; Asmal, A.; Boucher, B.J. and Karamanos, B.: Peripheral metabolism in obesity; the effects of weight reduction by diet and fenfluramine. South African Medical Journal 45 (Suppl.): 21 (1971).Google Scholar
  46. Cabezas Cerrato, J.C.; Catalan, E.; Vila, T. and Fernandez-Cruz, A.: Secrecion de insulina y tolerancia hidrocarbonada en la obesidad esencial de la mujer (Influencia de la fenformina, fenfluramina, y d-amfetamina). Revista Clinica Espanola 120: 337 (1973).Google Scholar
  47. Cabezas Cerrato, J.; Gomez Perez, M.; Marco-Mur, A.L.; Camarero, E. and Fernandez-Cruz, A.: Influencia de la fenfluramina sobre la tasa semanal de adelgazamiento en la obesidad. Revista Clinica Espanola 132: 47 (1974).PubMedGoogle Scholar
  48. Cahal, D.A.: Appetite suppressants and pulmonary hypertension. Lancet 1: 947 (1969).PubMedCrossRefGoogle Scholar
  49. Cameron, D.C.; Kennedy, W.P.U.; Samuel, P. and Crompton, G.K.: Fenfluramine in corticosteroid-induced obesity. Current Medical Research and Opinion 1: 153 (1972).PubMedCrossRefGoogle Scholar
  50. Campbell, D.B.: Gas Chromatographic measurement of levels of fenfluramine and norfenfluramine in human plasma red cells and urine following therapeutic doses. Journal of Chromatography 49: 442 (1970).PubMedCrossRefGoogle Scholar
  51. Campbell, D.B.: Plasma concentration of fenfluramine and its metabolite, norfenfluramine, following single and repeated oral administration. British Journal of Pharmacology 43: 465 (1971).Google Scholar
  52. Campbell, D.B.: Absorption, distribution, and metabolism of fenfluramine. La Vie Medicale au Canada Francais 2: 34 (1973).PubMedGoogle Scholar
  53. Campbell, D.B. and Moore, B.W.R.: Fenfluramine over-dosage. Lancet 2: 1307 (1969).PubMedGoogle Scholar
  54. Canivet, J. and Roux, P.: Emploi de la medication anorexigene dans le traitement du diabète sucre. Semaine des Hopitaux de Paris 39: 587 (1962).Google Scholar
  55. Chandler, P.T.; Dannenburg, W.N.; Polan, CE. and Thompson, N.R.: Effect of fenfluramine on appetite and lipid metabolism of the young ruminant. Journal of Dairy Science 53: 1747 (1970).PubMedCrossRefGoogle Scholar
  56. Chase, T.M. and Shoulson, I.: Behavioural and biochemical effects of fenfluramine in patients with neurological disease. Postgraduate Medical Journal 51 (Suppl. 1): 101 (1975).Google Scholar
  57. Chhina, G.S.; Kang, H.K.; Singh, B. and Anand, B.K.: Effect of fenfluramine on the electrical activity of the hypothalamic feeding centres. Physiology and Behaviour 7: 433 (1971).CrossRefGoogle Scholar
  58. Chremos, A.N.; Dannenburg, W.N. and Noble, R.E.: Plasma lipid and weight changes of obese subjects treated with fenfluramine. Diabetes 20 (Suppl. 1): 351 (1971).Google Scholar
  59. Clineschmidt, B.V.: 5,6-Dihydroxytryptamine: suppression of the anorexigenic action of fenfluramine. European Journal of Pharmacology 24: 405 (1973).PubMedCrossRefGoogle Scholar
  60. Clineschmidt, B.V.; McGuffin, J. and Werner, A.: Role of monoamines in the anorexigenic actions of fenfluramine, amphetamine, and p-chloroamphetamine. European Journal of Pharmacology 27: 313 (1974).PubMedCrossRefGoogle Scholar
  61. Costa, E.; Groppetti, A. and Revuelta, A.: Action of fenfluramine on monoamine stores of rat tissue. British Journal of Pharmacology 41: 57 (1971).PubMedCrossRefGoogle Scholar
  62. Costa, E. and Revuelta, A.: Norfenfluramine and serotonin turnover rate in the rat brain. Biochemical Pharmacology 21: 2385 (1972).PubMedCrossRefGoogle Scholar
  63. Cotterill, J.A.; Cunliffe, W.J. and Williamson, B.: Sebum excretion rate and biochemistry in patients with acne vulgaris treated by oral fenfluramine. British Journal of Dermatology 85: 127 (1971).PubMedCrossRefGoogle Scholar
  64. Court, J.M.: The management of obesity. Drugs 4: 411 (1972a).PubMedCrossRefGoogle Scholar
  65. Court, J.M.: A trial of fenfluramine in children with obesity associated with reduced muscle activity. South African Medical Journal 46: 132 (1972b).PubMedGoogle Scholar
  66. Court, J.M.: Obesity as an early disorder of childhood. Patient Management 4 (No. 3): 3 (1975).Google Scholar
  67. Cox, R.H. and Maickel, R.P.: Comparison of anorexigenic and behavioural potency of phenylethylamines. Journal of Pharmacology and Experimental Therapeutics 181: 1 (1972).PubMedGoogle Scholar
  68. Craddock, D.: Obesity and its management. 2nd edition (Livingstone, Edinburgh 1973).Google Scholar
  69. Dannenburg, W.N.; Kardian, B.C. and Norrell, L.Y.: Fenfluramine and triglyceride synthesis by microsomes of the intestinal mucosa in the rat. Archives Internationales de Pharmacodynamie et de Therapie 201: 115 (1973).PubMedGoogle Scholar
  70. Dannenburg, W.N. and Ward, J.W.: Inhibitory effect of fenfluramine on pancreatic lipase activity. Archives Internationales de Pharmacodynamie et de Therapie 191: 58 (1971).PubMedGoogle Scholar
  71. Darmady, J.M.: Diazepam for fenfluramine intoxication. Archives of Disease in Childhood 49: 328 (1974).PubMedCrossRefGoogle Scholar
  72. Datey, K.K.; Kelkar, P.N. and Pandya, R.S.: Fenfluramine in the management of obesity. British Journal of Clinical Practice 27: 373 (1973).PubMedGoogle Scholar
  73. Davidson, D.L.; Mawdsley, C.; Campbell, C. and Munro, J.F.: Fenfluramine and epilepsy. Postgraduate Medical Journal 51 (Suppl. 1): 171 (1975).Google Scholar
  74. Divekar, M.V.; Sundaram, P.; Tendulkar, U.R.; Coovergi, N.D.; Shah, J.R. and Masic, S.S.: Carbohydrate intolerance in obese adults and efficacy of fenfluramine in different types of obesity. Journal of the Diabetes Association of India 14: 109 (1974).Google Scholar
  75. Duhault, J. and Fenard, S.: Etude sur l’excretion, la localisation, et le metabolisme d’une nouvelle substance anorexigene: le fenfluramine. Archives Internationales de Pharmacodynamie et de Therapie 158: 251 (1965).PubMedGoogle Scholar
  76. Duncan, E.H.; Hyde, C.A.; Regan, N.A. and Sweetman, B.: A clinical trial of fenfluramine (Ponderax) in general practice. British Journal of Clinical Practice 19: 451 (1965).PubMedGoogle Scholar
  77. Duncan, L.J.P.: Anorexiants and oral contraceptives. Practitioner 208: 852 (1972).Google Scholar
  78. Durnin, J.V.G.A. and Womersley, J.: The metabolic effects and the composition of the tissue lost in weight reduction by obese patients on treatment with fenfluramine. British Journal of Pharmacology 49: 115 (1973).PubMedCrossRefGoogle Scholar
  79. Dykes, J.R.W.: The effect of a low-calorie diet with or without fenfluramine, and fenfluramine alone, on the glucose tolerance and insulin secretion of overweight non-diabetics. Postgraduate Medical Journal 49: 314 (1973a).PubMedCrossRefGoogle Scholar
  80. Dykes, J.W.: The effect of a low-calorie diet with or without fenfluramine on the glucose tolerance and insulin secretion of obese maturity onset diabetics. Postgraduate Medical Journal 49: 318 (1973b).PubMedCrossRefGoogle Scholar
  81. Editorial: Drugs causing weight gain. British Medical Journal 1: 168 (1974).Google Scholar
  82. Eid, E.E.: Follow-up study of physical growth of children who had excessive weight gain in the first six months of life. British Medical Journal 2: 74 (1970).PubMedCrossRefGoogle Scholar
  83. Elliott, B.W.: A collaborative investigation of fenfluramine: anorexigenic with sedative properties. Current Therapeutic Research 12: 502 (1970).PubMedGoogle Scholar
  84. Engelhardt, A.; Kroneberg, G.; Stoepel, S. and Stotzer, H.: On the effects of sympathomimetic substances on the systemic and pulmonary circulation following acute and chronic administration. Paper presented to the European Society for the Study of Drug Toxicity, Uppsala, Sweden, 1970.Google Scholar
  85. Evans, J.W.: Double-blind trial of fenfluramine as an aid to stop smoking. South African Medical Journal 45 (Suppl.): 33 (1971).Google Scholar
  86. Evans, E.; Miller, D.S.; Samuel, P.E. and Burland, W.L.: The effects of fenfluramine and 780 SE on fat absorption. Postgraduate Medical Journal 51 (Suppl. 1): 111 (1975).Google Scholar
  87. Everitt, B.J. and Hacket, N.B.: Central stimulant action of fenfluramine in the rat. British Journal of Pharmacology 44: 342 (1972).Google Scholar
  88. Fink, M.; Shapiro, D.M. and Itil, T.N.: EEG profiles of fenfluramine, amobarbital and dextroamphetamine in normal volunteers. Psychopharmacologia 22: 369 (1971).PubMedCrossRefGoogle Scholar
  89. Firth, H.; Lewis, S.A.; Ogunremi, O.O. and Oswald, I.: The effect of acute administration of m-trifluoro-methylpheny1-1-(benzolyloxy)-ethylamino-2-propane (780 SE) and fenfluramine on human sleep. British Journal of Pharmacology 39: 462 (1970).PubMedCrossRefGoogle Scholar
  90. Fleisher, M.R. and Campbell, D.B.: Fenfluramine overdosage. Lancet 2: 1306 (1969).PubMedGoogle Scholar
  91. Follows, O.J.: A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients. British Journal of Clinical Practice 25: 236 (1971).PubMedGoogle Scholar
  92. Foxwell, M.H.; Funderburk, W.H. and Ward, J.W.: Studies on the site of action of a new anorectic agent, fenfluramine. Journal of Pharmacology and Experimental Therapeutics 165: 60 (1969).PubMedGoogle Scholar
  93. Franko, B.V.; Honkomp, L.H. and Ward, J.W.: Cardiovascular and autonomic effects of fenfluramine. Journal of Pharmacy and Pharmacology 17: 222 (1965).PubMedCrossRefGoogle Scholar
  94. Frayn, K.N.; Hedges, A. and Kirby, M.M.: Stimulation by fenfluramine of glucose uptake into skeletal muscle in vitro. Hormone and Metabolic Research 6: 86 (1974).PubMedCrossRefGoogle Scholar
  95. Freter, K.; Gotz, M. and Oliver, J.T.: A new group of anorexigenic compounds. Journal of Medicinal Chemistry 13: 1228 (1970).PubMedCrossRefGoogle Scholar
  96. Funderburk, W.H.; Hash, A.M. and Hazelwood, J.C.: Species-dependent effects of fenfluramine on the central nervous system. Journal of Pharmacy and Pharmacology 23: 509 (1971).PubMedCrossRefGoogle Scholar
  97. Fuxe, K.; Farnebo, L.O.; Hamberger, B. and Ogren, S.O.: On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine. Postgraduate Medical Journal 51 (Suppl. 1): 31 (1975).Google Scholar
  98. Gagnon, M.A.; Bordeleau, J.W. and Tetreault, L.: Fenfluramine: Study of its central action through its effects on sleep. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1: 74 (1969a).Google Scholar
  99. Gagnon, M.A.; Tetreault, L. and Bordeleau, J.M.: Psychometric studies on sleep for the evaluation of central effects of drugs. The effects of fenfluramine on sleep. Activitas Nervosa Superior 21: 202 (1969b).Google Scholar
  100. Gaind, R.: Fenfluramine (Ponderax) in the treatment of obese psychiatric out-patients. British Journal of Psychiatry 115: 963 (1969).PubMedCrossRefGoogle Scholar
  101. Gaind, R.: Psychological aspects in the aetiology and treatment of obesity. South African Medical Journal 45 (Suppl.): 36 (1971).Google Scholar
  102. Galloway, D.B.; Logie, A.W. and Petrie, J.C.: Prolonged-action fenfluramine in non-diabetic patients with refractory obesity. Postgraduate Medical Journal 51 (Supp. 1): 151 (1975).Google Scholar
  103. Garattini, S.; Buczko, W.; Jon, A. and Samanin, R.: The mechanism of action of fenfluramine. Postgraduate Medical Journal 51 (Suppl. 1): 23 (1975).Google Scholar
  104. Garay Lillo, J.; Molina Plasencia, M. and Montes Chulia, J.: Ensayo clinico cor fenfluramine en cardiopatas obesos. Revista de Medicina 38: 216 (1970).Google Scholar
  105. Garrow, J.S.; Belton, E.A. and Daniels, A.: A controlled investigation of the ‘Glycoliptic’ action of fenfluramine. Lancet2: 559 (1972).PubMedCrossRefGoogle Scholar
  106. Gaultier, M.; Efthymiou, M.L. and Cottereau, C.: Acute intoxication from recent anorexigenics (amphetamines excluded). Journal European de Toxicologie 1: 55 (1968).Google Scholar
  107. Gavin, J.R.; Gorden, P.; Roth, J.; Archer, J.A. and Buell, D.N.: Characteristics of the human lymphocyte insulin receptor. Journal of Biological Chemistry 248: 2202 (1973).PubMedGoogle Scholar
  108. General Practitioner Clinical Trials: Hypotensive effect of fenfluramine in the treatment of obesity. Practitioner 207: 101 (1971).Google Scholar
  109. Gilbert, D.L.; Franko, B.V.; Ward, J.W.; Woodard, G. and Courtney, K.D.: Toxicologic studies of fenfluramine. Toxicology and Applied Pharmacology 19: 705 (1971).PubMedCrossRefGoogle Scholar
  110. Gold, R.G.; Gordon, H.E.; da Costa, R.W.D.; Porteus, I.B. and Kimber, K.J.: Fenfluramine overdosage. Lancet 2: 1306 (1969).PubMedCrossRefGoogle Scholar
  111. Goldrick, R.B.; Havenstein, N. and Whyte, H.M.: Effects of calorie restriction and fenfluramine on weight loss and personality profiles of patients with longstanding obesity. Australian and New Zealand Journal of Medicine 3: 131 (1973).PubMedCrossRefGoogle Scholar
  112. Goldrick, R.B.; Nestel, P.J. and Havenstein, N.: Comparison of a new anorectic agent AN 448 with fenfluramine in the treatment of refractory obesity. Medical Journal of Australia 1: 882 (1974).PubMedGoogle Scholar
  113. Gotestam, K.G. and Andersson, B.E.: Assessment of reinforcing properties of amphetamine analogues in self-administering rats. Postgraduate Medical Journal 51 (Suppl. 1): 76 (1975).Google Scholar
  114. Gotestam, K.G. and Gunne, L.M.: Subjective effects of two anorexigenic agents, fenfluramine and AN 448, in amphetamine-dependent subjects. British Journal of Addiction 67: 39 (1972).CrossRefGoogle Scholar
  115. Goudie, A.J. and Taylor, M.: Time sampling of rat exploratory behaviour. A reliable screening test for CNS effects of anorexic agents. Psychopharmacologia 35: 1 (1974).CrossRefGoogle Scholar
  116. Greenwood, M.: Side-effects associated with long-term fenfluramine therapy. La Vie Medicale au Canada Francais 2: 248 (1973).PubMedGoogle Scholar
  117. Gunne, L.M.; Antonijevic, S. and Jonsson, J.: Effect of fenfluramine on steady state plasma levels of amitriptyline. Postgraduate Medical Journal 51 (Suppl. 1): 113 (1975).Google Scholar
  118. Hadler, AJ.: Fenfluramine, a new anorexigenic agent. Journal of Clinical Pharmacology 11: 52 (1971).CrossRefGoogle Scholar
  119. Haines, A.P. and Shoenberg, P.J.: Hyperpyrexia and overdose. British Medical Journal 1: 632 (1972).PubMedCrossRefGoogle Scholar
  120. Harding, T.: Fenfluramine dependence. British Medical Journal 3: 305 (1971).PubMedCrossRefGoogle Scholar
  121. Harding, T.: Depression following fenfluramine withdrawal. British Journal of Psychiatry 121: 338 (1972).PubMedCrossRefGoogle Scholar
  122. Harrison, L.C.; King-Roach, A.; Martin, F.I.R. and Melick, R.A.: The effect of fenfluramine on insulin binding and on basal insulin-stimulated oxidation of 1-14C-glucose by human adipose tissue. Postgraduate Medical Journal 51 (Suppl. 1): 106 (1975).Google Scholar
  123. Harvey, J.A. and McMaster, S.E.: Fenfluramine — Evidence for a neurotoxic action on midbrain and a long-term depletion of serotonin. Psychopharmacology Communications 1: 217 (1975).PubMedGoogle Scholar
  124. Hawks, D.V.: Unusual effect of fenfluramine. British Medical Journal 1: 238 (1970).PubMedCrossRefGoogle Scholar
  125. Hayes, T.M. and Lewis, B.M.: DNA synthesis in adipose tissue. Postgrad. med. J. 51 (Suppl. 1): 83 (1975).Google Scholar
  126. Herold, E.; Kemper, F. and Opitz, K.: Einfluss appetithemmender Substanzen auf Kohlenhydrat und Fettsaure — Stoffwechsel. Arzneimittel — Forschung 15: 657 (1965).PubMedGoogle Scholar
  127. Hill, R.C. and Turner, P.: Fenfluramine and critical flicker frequency. J. Pharm. Pharmacol. 19: 337 (1967).PubMedCrossRefGoogle Scholar
  128. Hollingsworth, D.R. and Amatruda, T.T.: Toxic and therapeutic effects of EMTP in obesity. Clinical Pharmacology and Therapeutics 10: 540 (1969).PubMedGoogle Scholar
  129. Holmstrand, J. and Jonsson, J.: Subjective effects of two anorexigenic agents — fenfluramine and AN 448 in normal subjects. Postgraduate Medical Journal 51 (Suppl. 1): 180 (1975).Google Scholar
  130. Hooper, A.C.: Comparison of fenfluramine (with ad libitum food intake) with 1000-calorie diet in obesity. Journal of the Irish Medical Association 65: 35 (1972).PubMedGoogle Scholar
  131. Hooper, A.C.: A clinical trial of a new fenfluramine preparation (Ponderax PA). Postgraduate Medical Journal 51 (Suppl. 1): 155 (1975).Google Scholar
  132. Hossain, M. and Campbell, B.C.: Fenfluramine and methylcellulose in the treatment of obesity. The relationship between plasma drug concentrations and therapeutic efficacy. Postgraduate Medical Journal 51 (Suppl. 1): 175 (1975).Google Scholar
  133. Hoyer, I. and Van Zwieten, P.A.: The central hypotensive action of amphetamine, ephedrine, phentermine, chlorphentermine, and fenfluramine. Journal of Pharmacy and Pharmacology 24: 452 (1972).PubMedCrossRefGoogle Scholar
  134. Hughes, B.D.: Double-blind trial in anxiety and tension in patients referred to psychiatric out-patients department. South African Medical Journal 45 (Suppl.): 37 (1971).Google Scholar
  135. Ijichi, I.: Pharmacological studies of fenfluramine. Shikoku Acta Medica 27: 313 (1971).Google Scholar
  136. Imlah, N.W.: Unusual effect of fenfluramine. British Medical Journal 2: 178 (1970).PubMedCrossRefGoogle Scholar
  137. Innes, J.A.; Campbell, I.W.; Millar, J. and Munro, J.F.: A comparison of the efficacy and acceptability of fenfluramine tablets (BP) and prolonged action capsules (60mg). Postgraduate Medical Journal 51 (Suppl. 1): 156 (1975).Google Scholar
  138. Jackson, W.P.U.: Fenfluramine trials in a diabetic clinic. S. Afr. med. J. 45 (Suppl.): 29 (1971).Google Scholar
  139. Jespersen, S. and Bonaccorsi, A.: Anti-amphetamine activity of fenfluramine and S992 in the isolated rat tail artery. Journal of Pharmacy and Pharmacology 21: 776 (1969).PubMedCrossRefGoogle Scholar
  140. Jespersen, S. and Scheel-Kruger, H.: Antagonism by methysergide of the 5-hydroxytryptamine-like action of toxic doses of fenfluramine in dogs. Journal of Pharmacy and Pharmacology 22: 637 (1970).PubMedCrossRefGoogle Scholar
  141. Johnson, D.N.; Funderburk, W.H. and Ward, J.W.: Effects of fenfluramine on sleep-wakefulness in cats. Psychopharmacologia 20: 1 (1971a).PubMedCrossRefGoogle Scholar
  142. Johnson, D.N.; Funderburk, W.H. and Ward, J.W.: Comparative effects of ten anorectic drugs on sleepwakefulness in cats. European Journal of Pharmacology 15: 176 (1971b).PubMedCrossRefGoogle Scholar
  143. Jones, H.S.: Fenfluramine used as a substitute for methyl-amphetamine and dexamphetamine in the treatment of dependence of these drugs. South African Medical Journal 45 (Suppl.): 31 (1971).Google Scholar
  144. Jori, A. and Dolfini, E.: On the effect of anorectic drugs on striatal homovanillic acid in rats. Pharmacological Research Communications 6: 175 (1974).PubMedCrossRefGoogle Scholar
  145. Kaufmann, N.A. and Blondheim, S.H.: Action of fenfluramine. Lancet 1: 104 (1973).PubMedCrossRefGoogle Scholar
  146. Kaye, J.; Galton, DJ. and Tomlin, S.: The effect of fenfluramine and its derivatives on triglyceride secretion by the liver of the rabbit. Postgraduate Medical Journal 51 (Suppl. 1): 91 (1975).Google Scholar
  147. Khanna, S.; Nayar, U. and Anand, B.K.: Effect of fenfluramine on the single neuron activities of the hypothalamic feeding centres. Physiology and Behaviour 8: 453 (1972).CrossRefGoogle Scholar
  148. Kirby, M.J. and Turner, P.: Effect of the (−)- and (+)-isomers of fenfluramine and norfenfluramine on glucose uptake by the isolated rat hemidiaphragm. British Journal of Pharmacology 51: 121P (1974a).Google Scholar
  149. Kirby, M.J. and Turner, P.: Effect of fenfluramine and norfenfluramine on glucose uptake by the isolated rat diaphragm. British Journal of Pharmacology 50: 477 (1974b).Google Scholar
  150. Kirby, M.J. and Turner, P.: Dose-related effect of fenfluramine and norfenfluramine on glucose uptake into human isolated skeletal muscle. British Journal of Clinical Pharmacology 1: 511 (1974c).PubMedCrossRefGoogle Scholar
  151. Kirby, M.J. and Turner, P.: Fenfluramine and norfenfluramine on glucose uptake into skeletal muscle. Postgraduate Medical Journal 51 (Suppl. 1): 69 (1975).Google Scholar
  152. Kneebone, G.M.: Drug therapy: An effective treatment for obesity in childhood. Medical Journal of Australia 2: 663 (1968a).Google Scholar
  153. Kneebone, G.M.: Fenfluramine in the treatment of obesity. Medical Journal of Australia 2: 833 (1968b).PubMedGoogle Scholar
  154. Kneebone, G.M.: The non-anorectic effects of fenfluramine hydrochloride at the clinical level. South African Medical Journal 45 (Suppl.): 41 (1971a).Google Scholar
  155. Kneebone, G.M.: The non-anorectic effects of fenfluramine hydrochloride at an experimental level. South African Medical Journal 45 (Suppl): 20 (1971b).Google Scholar
  156. Kramer, R.; Rubicek, M. and Turner, P.: The role of norfenfluramine in fenfluramine-induced mydriasis. Journal of Pharmacy and Pharmacology 25: 575 (1973).PubMedCrossRefGoogle Scholar
  157. Krasner, N.; Moore, M.R.; Dow, J.; Thompson, G.G. and Goldberg, A.: Fenfluramine and 780 SE in experimental alcoholism in rats. Postgraduate Medical Journal 51 (Suppl. 1): 72 (1975).Google Scholar
  158. Krebs, H.; Bindra, D. and Campbell, J.F.: Effects of amphetamine on neuronal activity in the hypothalamus. Physiology and Behaviour 4: 685 (1969).CrossRefGoogle Scholar
  159. Kundig, H.: Studies in primates of the manifestations and treatment of fenfluramine intoxication. South African Medical Journal 45 (Suppl.): 11 (1971).Google Scholar
  160. Lawson, A.A.H.; Roscoe, P.; Strong, J.A.; Gibson, A. and Peattie, P.: Comparison of fenfluramine and metformin in treatment of obesity. Lancet 2: 437 (1970).PubMedCrossRefGoogle Scholar
  161. Le Douarec, J.C. and Neveu, C: Pharmacology and biochemistry of fenfluramine. In Costa and Garattini, Amphetamine and Related Compounds, p.75 (Raven Press, New York 1970).Google Scholar
  162. Lele, R.D.; Joshi, U.R. and Nathwani, A.N.: A double-blind clinical trial of fenfluramine. British Journal of Clinical Practice 26: 79 (1972).PubMedGoogle Scholar
  163. Lesses, M.F. and Meyerson, A.: Human autonomie pharmacology. XVI. Benzedrine sulfate as an aid in the treatment of obesity. New England Journal of Medicine 218: 119 (1938).CrossRefGoogle Scholar
  164. Levin, A.: The non-medical misuse of fenfluramine by drug-dependent young South Africans. Postgraduate Medical Journal 51 (Suppl. 1): 183 (1975).Google Scholar
  165. Lewis, S.A.: Comparative effects of some amphetamine derivates on human sleep. In Costa and Garattini, Amphetamine and Related Compounds, p.873 (Raven Press, New York 1970).Google Scholar
  166. Lewis, S.A.; Oswald, I. and Dunleavy, D.L.F.: Chronic fenfluramine administration. Some cerebral effects. British Medical Journal 3: 67 (1971).Google Scholar
  167. Lorber, J. and Greenwood, M.: The treatment of severe childhood obesity with fenfluramine. A controlled therapeutic trial. South African Medical Journal 45 (Suppl.): 40 (1971).Google Scholar
  168. Lüllmann-Rauch, R. and Reil, G.H.: Fenfluramine-induced ultrastructural alterations in tissues of rats and guinea pigs. Naunyn-Schmiedeberg’s Archives of Pharmacology 285: 175 (1974).PubMedCrossRefGoogle Scholar
  169. Luntz, G.R.W.N. and Reuter, C.J.: A six-month study of a carbohydrate-restricted diet in the management of maturity-onset diabetes and an evaluation of fenfluramin in patients unresponsive to this diet. Postgraduate Medical Journal 57 (Suppl. 1): 129 (1975).Google Scholar
  170. Mace, P.; Malcolm, A.D.; Outar, K.P. and Pawan, G.L.S.: Comparative effects of four antiobesity agents on blood plasma lipids in man. Proceedings of the Nutrition Society 31: 14A (1972).PubMedGoogle Scholar
  171. Maickel, R.P. and Johnson, S.A.: Effects of various anorexigenic agents on open field behaviour in rats. Research Communications in Chemical Pathology and Pharmacology 6: 733 (1973).PubMedGoogle Scholar
  172. Maneshka, S.: Prolonged action fenfluramine capsule versus fenfluramine tablets in general practice. British Journal of Clinical Practice 29: 12 (1975).Google Scholar
  173. Mantegazza, P.; Muller, E.E.; Naimzada, M.K. and Riva, M.: Studies on the lack of correlation between hyperthermia, hyperactivity, and anorexia induced by amphetamine. In Costa and Garattini, Amphetamine and Related Compounds, p.559 (Raven Press, New York 1970).Google Scholar
  174. Marsh, J.B.; Guitani, A.; Bartosek, I. and Bizzi, A.: Correlation between bile secretion and triglyceride release in perfused rat liver and some effects of fenfluramine. Proceedings of the Society for Experimental Biology and Medicine 139: 753 (1972).PubMedGoogle Scholar
  175. Matthew, H.: Fenfluramine overdosage. Lancet 1: 42 (1970).PubMedCrossRefGoogle Scholar
  176. Morgan, C.D.; Cattabeni, F. and Costa, E.: Methamphetamine, fenfluramine, and their N-dealkylated metabolites. Effects on monoamine concentrations in rat tissues. Journal of Pharmacology and Experimental Therapeutics 180: 127 (1972a).PubMedGoogle Scholar
  177. Morgan, C.D.; Lofstrandh, S. and Costa, E.: Amphetamine analogues and brain amines. Life Sciences (Part I) 11: 83 (1972b).Google Scholar
  178. Mroczek, W.J.; Lee, W.R. and Finnerty, F.A.: Circulatory effects of fenfluramine in obese hypertensive patients. Current Therapeutic Research 16: 1197 (1974).PubMedGoogle Scholar
  179. Mullen, A. and Wilson, C.W.M.: Fenfluramine and dreaming. Lancet 2: 594 (1974).PubMedCrossRefGoogle Scholar
  180. Munro, J.F.: The management of obesity. In Robertson and Proudfoot, Symposium on Anorexia Nervosa and Obesity, p.100 (Royal College of Physicians, Edinburgh 1973a).Google Scholar
  181. Munro, J.F.: The management of obesity. British Journal of Hospital Medicine 10: 8 (1973b).Google Scholar
  182. Munro, J.F.; MacCuish, A.C.; Wilson, E.M. and Duncan, L.J.P.: Comparison of continuous and intermittent anorectic therapy in obesity. British Medical Journal 1: 352 (1968).PubMedCrossRefGoogle Scholar
  183. Munro, J.F.; Seaton, D.A. and Duncan, L.J.P.: Treatment of refractory obesity with fenfluramine. British Medical Journal 2: 624 (1966).PubMedCrossRefGoogle Scholar
  184. O’Connor, C.A. and Brodbin, P.: Fenfluramine in obesity. British Journal of Clinical Practice 24: 118 (1970).PubMedGoogle Scholar
  185. Offermeier, J. and Potgieter, B.: On the possible mechanisms of central stimulant actions of some phenethylamine derivatives. South African Medical Journal 46: 72 (1972).PubMedGoogle Scholar
  186. Offermeier, J. and Potgieter, B.: Some effects of fenfluramine and its derivatives on the central catecholaminergic systems of mice. Postgraduate Medical Journal 51 (Suppl. 1): 61 (1975).Google Scholar
  187. Opitz, K.: Effect of fenfluramine on alcohol and saccharin consumption in the rat. South African Medical Journal 46: 742 (1972).PubMedGoogle Scholar
  188. Opitz, K. and Weischer, M.L.: Die Ausscheidung anorexigene Phenylalkylamine mit dem Harn. Arzneimittel-Forschung 16: 1311 (1966).PubMedGoogle Scholar
  189. Oswald, I.: Drugs and sleep. Pharmacological Reviews 20: 273 (1968).PubMedGoogle Scholar
  190. Oswald, I.: Effects on sleep of amphetamine and its derivatives. In Costa and Garattini, Amphetamine and Related Compounds, p.865 (Raven Press, New York 1970).Google Scholar
  191. Oswald, I.; Jones, H.S. and Mannerheim, J.E.: The effects of two slimming drugs on sleep. British Medical Journal 1: 796 (1968).PubMedCrossRefGoogle Scholar
  192. Oswald, I. and Lewis, S.A.: Addiction or dependence. British Medical Journal 3: 229 (1971).CrossRefGoogle Scholar
  193. Oswald, I.; Lewis, S.A.; Dunleavy, D.L.F.; Brezinova, V. and Briggs, M.: Drugs of dependence though not of abuse: fenfluramine and imipramine. British Medical Journal 3: 70 (1971).PubMedCrossRefGoogle Scholar
  194. Owen, J.H.: Prolonged action fenfluramine in general practice. British Journal of Clinical Practice 29: 13 (1975).PubMedGoogle Scholar
  195. Pawan, G.L.S.: Effects of fenfluramine on blood-lipids in man. Lancet 1: 498 (1969).PubMedCrossRefGoogle Scholar
  196. Pawan, G.L.S.: Metabolic studies of the effect of fenfluramine in man and the mouse. In Costa and Garattini, Amphetamine and Related Compounds, p.641 (Raven Press, New York 1970).Google Scholar
  197. Pearce, J.B.: Fenfluramine in mania. Lancet 1: 427 (1973).PubMedCrossRefGoogle Scholar
  198. Persson, I.; Andersen, U. and Deckert, T.: Treatment of obesity with fenfluramine. European Journal of Clinical Pharmacology 6: 93 (1973).PubMedCrossRefGoogle Scholar
  199. Petrie, J.C.; Mowat, J.A.; Bewsher, P.D. and Stowers, M.: Metabolic effects of fenfluramine. A double-blind study. Postgraduate Medical Journal 51 (Suppl. 1): 139 (1975).PubMedGoogle Scholar
  200. Poire, R.; Rombach, F. and Crance, J.P.: Obesite et fenfluramine (768 S). Experiences de trois ans d’utilisation prolongee et controlee du medicament en milieu psychiatrique hospitalies. Annales Medico-Psychologiques 1: (1966).Google Scholar
  201. Poskitt, E.M.E, and Rayner, P.H.: Fenfluramine and growth hormone release. British Medical Journal 3: 349 (1973).Google Scholar
  202. Prime, F.J.: Dangers of certain appetite suppressants. British Medical Journal 2: 177 (1969).CrossRefGoogle Scholar
  203. Prime, F.J.: An assessment of the value of antiobesity treatment in a chest clinic. South African Medical Journal 45 (Suppl.): 38 (1971).Google Scholar
  204. Raich, W.A.; Rickeis, K. and Raab, E.: A double-blind evaluation of fenfluramine in anxious somatising neurotic medical clinic patients. Current Therapeutic Research 8: 31 (1966).PubMedGoogle Scholar
  205. Ramirez Soto, E. and Delgado Urdapilleta, J.: Fenfluramina, droga anorexigenica en le practica obstetrica. Ginecologia y Obstetricia de Mexico 15: 425 (1969).Google Scholar
  206. Rayner, P.H.W.: Fenfluramine in childhood obesity. Clinical experience, and effects of fenfluramine and weight loss on blood glucose, plasma insulin, and plasma growth hormone response to an oral glucose load. South African Medical Journal 45 (Suppl.): 28 (1971).Google Scholar
  207. Rayner, P.H.W, and Court, J.M.: The effect of dietary restriction and anorectic drugs on linear growth velocity in childhood obesity. Postgraduate Medical Journal 51 (Suppl. 1): 116 (1975).Google Scholar
  208. Richards, A.J.: Fenfluramine overdosage. Lancet 2: 1367 (1969).PubMedCrossRefGoogle Scholar
  209. Riley, I.; Corson, J.; Haider, I. and Oswald, I.: Fenfluramine overdosage. Lancet 2: 1162 (1969).PubMedCrossRefGoogle Scholar
  210. Rooyen, R.J. van, and Merwe, M. van der: Comparison of diethylpropion (Tenuate Dospan) and fenfluramine. Medical Proceedings 17: 420 (1971).Google Scholar
  211. Rosenvinge, H.P.: Abuse of fenfluramine. British Medical Journal 1: 735(1975).PubMedCrossRefGoogle Scholar
  212. Runcie, J. and Toshner, D.: A controlled trial of fenfluramine in obese patients following therapeutic starvation. South African Medical Journal 45 (Suppl.): 43 (1971).Google Scholar
  213. Russell, T. and Reuter, C: Fenfluramine in the treatment of psoriasis. A preliminary report. Practitioner 214: 114 (1975).PubMedGoogle Scholar
  214. Ryan, E.M. and Szekely, M.: The effect of norfenfluramine on thermoregulation in the rabbit. Journal of Physiology 239: 39P (1974).Google Scholar
  215. Sainani, G.S.; Fulambarkar, A.M. and Khurana, B.K.: A double-blind clinical trial of fenfluramine in the treatment of obesity. British Journal of Clinical Practice 27: 136 (1973).PubMedGoogle Scholar
  216. Salans, L.B.; Knittle, J.L. and Hirsch, J.: The role of adipose cell size and adipose tissue insulin sensitivity in carbohydrate intolerance of human obesity. Journal of Clinical Investigation 47: 153 (1968).PubMedCrossRefGoogle Scholar
  217. Samanin, R.; Ghezzi, D.; Valzelli, L. and Garattini, S.: The effects of selective lesioning of brain serotoninor catecholamine-containing neurons on the anorectic activity of fenfluramine and amphetamine. European Journal of Pharmacology 19: 318 (1972).PubMedCrossRefGoogle Scholar
  218. Sananman, M.L.: Dyskinesias after fenfluramine. New England Journal of Medicine 291: 422 (1974).PubMedGoogle Scholar
  219. Sanchez-Medina, A. and Cortazar, J.: Double-blind clinical experience with fenfluramine in obese diabetics. Diabetes 18 (Suppl. 1): 371 (1969).Google Scholar
  220. Santer, N.: Fenfluramine overdosage. Lancet 2: 1422 (1969).PubMedCrossRefGoogle Scholar
  221. San-Yi, D.; Andrews, J.F. and Moore, R.E.: Thermogenic properties of fenfluramine. International Journal of Biometrics 15: 342 (1971).Google Scholar
  222. Sapeika, N.: Effect of fenfluramine on certain enźymes and on skin and amniotic fluid in tissue culture. Postgraduate Medical Journal 51 (Suppl. 1): 81 (1975).Google Scholar
  223. Sapeika, N.; Zwarenstein, H. and Kaplan, E.R.: Effect of fenfluramine and dexamphetamine on pyruvate kinase. Research Communications in Chemical Pathology and Pharmacology 2: 125 (1971).PubMedGoogle Scholar
  224. Schmitt, H. and Schmitt, H.: Interactions between reserpine and amphetamine on blood pressure. In Costa and Garattini, Amphetamine and Related Compounds, p.531 (Raven Press, New York 1970).Google Scholar
  225. Sedgwick, J.P.: A treatment for refractory obesity using fenfluramine without dietary restriction. British Journal of Clinical Practice 24: 251 (1970).PubMedGoogle Scholar
  226. Sedgwick, J.P.: A treatment for refractory obesity in general practice. South African Medical Journal 45 (Suppl.): 45 (1971).Google Scholar
  227. Sereday, M.S. de; Efran, H.R.; Compte, D.V. and Campo, M.A.R. del: Accion hipoglucemiante de la fenfluramina en diabeticos obesos. Prensa Medica Argentina 58: 1030 (1971).PubMedGoogle Scholar
  228. Shannon, P.J.; Leonard, D. and Kidson, M.A.: Fenfluramine and psychosis. British Medical Journal 3: 576 (1974).PubMedCrossRefGoogle Scholar
  229. Shoulson, I. and Chase, T.N.: Fenfluramine in man: Hypophagia associated with diminished serotonin turnover. Clinical Pharmacology and Therapeutics 17: 616 (1975).PubMedGoogle Scholar
  230. Silverstone, J.T.: Intermittent treatment with anorectic drugs. Practitioner 213: 245 (1974).PubMedGoogle Scholar
  231. Silverstone, J.T.: Obesity, Pathogenesis and Management (Medical and Technical Publishing, London 1975).CrossRefGoogle Scholar
  232. Silverstone, J.T.; Coope, R.M. and Begg, R.R.: A comparative trial of fenfluramine and diethylpropion in obesity. British Journal of Clinical Practice 24: 423 (1970).PubMedGoogle Scholar
  233. Silverstone, J.T.; Fincham, J. and Campbell, D.B.: The anorectic activity of fenfluramine. Postgraduate Medical Journal 51 (Suppl. 1): 167 (1975).Google Scholar
  234. Simpson, F.O. and Waal-Manning, J.: Use of fenfluramine in obese patients on antihypertensive therapy. South African Medical Journal 45 (Suppl.): 47 (1971).Google Scholar
  235. Sipes, I.G.; Ziance, R.J. and Buckley, J.P.: Some cardiovascular and autonomiac effects of fenfluramine hydrochloride. Journal of Pharmacology and Experimental Therapeutics 176: 220 (1971).PubMedGoogle Scholar
  236. Soulairac, A. and Soulairac, M.L.: Effect of amphetamine-like substances and 1-dopa on thirst, water-intake, and diuresis. In Costa and Garattini, Amphetamine and Related Compounds, p.819 (Raven Press, New York 1970).Google Scholar
  237. Southgate, P.J.; Mayer, S.R.; Boxall, E. and Wilson, A.B.: Some 5-hydroxytryptamine-like actions of fenfluramine: a comparison with amphetamine and diethylpropion. Journal of Pharmacy and Pharmacology 23: 600 (1971).PubMedCrossRefGoogle Scholar
  238. Spencer, D.J.: A short trial for fenfluramine in alcoholism. Journal of Alcoholism 7: 89 (1972).Google Scholar
  239. Sproule, B.C.: Treatment of the grossly obese with a high dosage of fenfluramine. South African Medical Journal 45 (Suppl.): 46 (1971).Google Scholar
  240. Sproule, B.C.: Treatment of the grossly obese with a high dosage of fenfluramine. South African Medical Journal 45 (Suppl.): 46 (1971).Google Scholar
  241. Srimal, R.C.; Singh, H.K. and Dhawa, B.N.: Experimental evidence for imipramine-like activity of fenfluramine. Archives Internationales de Pharmacodynamie et de Therapie 188: 320 (1970).PubMedGoogle Scholar
  242. Steel, J.M. and Briggs, M.: Withdrawal depression in obese patients after fenfluramine treatment. British Medical Journal 3: 26 (1972).PubMedCrossRefGoogle Scholar
  243. Steel, J.M.; Munro, J.F. and Duncan, L.J.P.: A comparative trial of different regimens of fenfluramine and phentermine in obesity. Practitioner 211: 232 (1973).PubMedGoogle Scholar
  244. Stunkard, A.; Rickeis, K. and Hesbacher, P.: Fenfluramine in the treatment of obesity. Lancet 1: 503 (1973).PubMedCrossRefGoogle Scholar
  245. Sulaiman, W.R. and Johnson, R.H.: Effect of fenfluramine on growth hormone release. British Medical Journal 2: 329 (1973).PubMedCrossRefGoogle Scholar
  246. Sulaiman, W.R.; Johnson, R.H. and Rennie, M.J.: Hormonal and metabolic studies of the action of fenfluramine in normal man, obesity, acromegaly, and diabetes mellitus. Postgraduate Medical Journal 51 (Suppl. 1): 121 (1975).Google Scholar
  247. Taitz, L.S.: Infantile overnutrition among artificially fed infants in the Sheffield region. British Medical Journal 1: 315 (1971).PubMedCrossRefGoogle Scholar
  248. Tang, A.M. and Kirch, I.D.: Appetite suppression and central nervous system stimulation in the rhesus monkey. Psychopharmacologia 21: 139 (1).Google Scholar
  249. Taylor, M.: The effects of fenfluramine on fixed ratio responding. Psychopharmacologia 32: 351 (1973).PubMedCrossRefGoogle Scholar
  250. Taylor, M.; Goudie, A.J. and Williams, A.: The effects of chronic fenfluramine administration on behaviour and body weight. Psychopharmacologia 31: 63 (1973).PubMedCrossRefGoogle Scholar
  251. Taylor, M.; Livesey, J.; Dempster, T. and Bunce, R.: The effects of acutely administered fenfluramine on activity and eating behaviour. Psychopharmacologia 21: 165 (1971).PubMedCrossRefGoogle Scholar
  252. Tewfik, G.I. and Jain, V.K.: Prolonged total fasting for obesity. Lancet 2: 1310 (1967).PubMedCrossRefGoogle Scholar
  253. Tomlinson, S.A. Lines, J.G. and Greenfield, M.A.M.: Effect of fenfluramine on the obesity and abnoral plasma lipids of patients with renal allografts. Postgraduate Medical Journal 51 (Suppl. 1): 162 (1975).CrossRefGoogle Scholar
  254. Tozer, R.; Campbell, D.B.; Leivers, P.G. and Edwards, J.A.: Bioavailability of prolonged action fenfluramine. Postgrad. med. J. 51 (Suppl. 1): 147 (1975).Google Scholar
  255. Traherne, J.B.: A clinical trial of fenfluramine. Practitioner 195: 677 (1965).PubMedGoogle Scholar
  256. Turtle, J.R. and Burgess, J.A.: Hypoglycaemic action of fenfluramine in diabetes mellitus. Diabetes 22: 858 (1973).PubMedGoogle Scholar
  257. Vignati, E.: Effects et indications de la fenfluramine dans le traitement de l’obesite. La Vie Medicale au Canada Francais 2: 166 (1973).PubMedGoogle Scholar
  258. Waal-Manning, H.J. and Simpson, F.O.: Fenfluramine in obese patients on various antihypertensive drugs. Double-blind controlled trial. Lancet 2: 1392 (1969).PubMedCrossRefGoogle Scholar
  259. Wakes-Miller, C: Fifty patients treated with fenfluramine by a family doctor compared to fifty clients attending a beauty farm. South African Medical Journal 45 (Suppl.): 16 (1971).Google Scholar
  260. Wells, M.V.: A trial of fenfluramine (PACAPS) and diet in overweight diabetic patients. Postgraduate Medical Journal 51 (Suppl. 1): 133 (1975).Google Scholar
  261. Wendel, H.A.: Addiction or dependence. British Medical Journal 3: 766 (1971).PubMedCrossRefGoogle Scholar
  262. Wesley-Hadzija, B.: Absorption and urinary excretion of fenfluramine and ethylamphetamine in subjects on different diets. Canadian Journal of Pharmaceutical Sciences 8: 101 (1973).Google Scholar
  263. Whichelow, M.J. and Butterfield, W.J.H.: Effects of fenfluramine on peripheral glucose metabolism in obesity. In Costa and Garattini, Amphetamine and Related Compounds, p.611 (Raven Press, New York 1970).Google Scholar
  264. White, A.G.; Beckett, A.H. and Brookes, L.G.: Fenfluramine overdosage. Brit. med. J. 1: 740 (1967).PubMedCrossRefGoogle Scholar
  265. Wilkins, P.S.W.: A trial of fenfluramine (Ponderax) in geriatrics. British Journal of Geriatric Practice 6: 9 (1969).Google Scholar
  266. Wilson, J.P.D. and Galton, D.J.: The effect of drugs on lipogenesis from glucose and palmitate in human adipose tissue. Hormone and Metabolic Research 3: 262 (1971).PubMedCrossRefGoogle Scholar
  267. Wilton, T.D.: Fenfluramine in complicated obesity. South African Medical Journal 48: 1324 (1974).PubMedGoogle Scholar
  268. Wilton, T.D.: Assessment of new formulation of fenfluramine in the management of the obese diabetic African. Postgraduate Medical Journal 51 (Suppl. 1): 134 (1975).Google Scholar
  269. Wolfsdorf, J. and Kanarek, K.S.: Fenfluramine overdosage in childhood. South African Medical Journal 46: 651 (1972).PubMedGoogle Scholar
  270. Woods, J.H. and Tessel, R.E.: Fenfluramine: Amphetamine congener that fails to maintain drug-taking behaviour in the rhesus monkey. Science 185: 1067 (1974).PubMedCrossRefGoogle Scholar
  271. Woodward, E.: Clinical experience with fenfluramine in the United States. In Costa and Garattini, Amphetamine and Related Compounds, p.685 (Raven Press, New York 1970).Google Scholar
  272. Yelnosky, J.O. and Lawlor, R.B.: A comparative study of the pharmacologic actions of amphetamine and fenfluramine. Archives Internationales de Pharmacodynamie et de Therapie 184: 374 (1970).PubMedGoogle Scholar
  273. Yudkin, J. and Miller, D.S.: Dietary-induced obesity and its treatment with fenfluramine and analogues. South African Medical Journal 45 (Suppl.): 49 (1971).Google Scholar
  274. Ziance, R.; Sipes, I.G.; Kinnard, W.J. and Buckley, J.P.: Central nervous system effects of fenfluramine hydrochloride. Journal of Pharmacology and Experimental Therapeutics 180: 110 (1972).PubMedGoogle Scholar
  275. Ziance, R. and Rutledge, C.O.: A comparison of the effects of fenfluramine and amphetamine on uptake, release, and catabolism of norepinephrine in rat brain. Journal of Pharmacology and Experimental Therapeutics 180: 118 (1972).PubMedGoogle Scholar
  276. Zolovick, A.J.W.; Stern, J.; Panksepp, J.E.; Jalowiec, J.E. and Morgane, P.J.: Sleep-waking patterns in cats after administration of fenfluramine and other monoaminergic-modulating drugs. Pharmacology, Biochemistry, and Behaviour 1: 41 (1973).CrossRefGoogle Scholar

Copyright information

© Adis Press 1975

Authors and Affiliations

  • R. M. Finder
    • 1
  • R. N. Brogden
    • 1
  • Phyllis R. Sawyer
    • 1
  • T. M. Speight
    • 1
  • G. S. Avery
    • 1
  1. 1.Australasian Drug Information ServicesBirkenhead, Auckland 10New Zealand

Personalised recommendations